Market News

Emverm provides a new option for patients with pinworm, whipworm, roundworm and hookworm in single or mixed infections.

Webinars will discuss tablet design and tool material selection, tool features and configuration and tooling maintenance and lifecycle management.

Significantly bolsters presence in high growth developing territories and the deal firmly establishes Recipharm’s emerging market strategy.

Focus on Microbiological contamination control and risk in pharmaceuticals, cosmetics and toiletries.

Merck obtains CE mark certification for consumables of Gavi and Geri as well as for the embryo culture media suite Gems.

Kalorama thinks Pfizer will continue to spotlight its vaccine business.

New company to develop novel cell-based cancer immunotherapies in China.

Adds selective muscarinic agonists discovered and developed by Heptares to Allergan's leading CNS pipeline.

Sales in Middle East to grow significantly in next 2 years.

Agreements relate to Eisai's global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the company's global epilepsy therapy, Fycompa (perampanel).

The merged company will combine deep technical expertise in process development and clinical manufacturing.

Allergan reiterates strong standalone growth profile and strategy following termination of Pfizer transaction.

Growth due to increasing complexity around affiliates’ roles.

Global market trends, growth and forecast to 2020.

New tablet attaches to the lining of the GI tract, resists being pulled away.

The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies to combine their expertise in research and development, intellectual property (IP) protection and management, and commercial acumen for more precise and efficient technology transfer.

In spite of similar approval numbers, the US continue to outpace Europe.

Rising prevalence of infectious diseases and cancer, significant nanotechnology research, and increasing demand for novel drug delivery systems are driving the nanotechnology market.

Purchase will expand Humanwell’s and PuraCap’s US Generics platform.

The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.

ISO 8655:2002 recommends using pipettes and tips that are sourced from the same manufacturer.

Enabling direct substitution in commercial enteric pharmaceutical formulations.

Progeny 1064nm handheld Raman analyser fully compliant with EP 2.2.48 to support pharmaceutical manufacturers with rapid and reliable raw material identification.

Company receives EPA honor for 11th consecutive year.

Company recognized with ENERGY STAR Award for fifth time.

Strategic acquisition of 14 prescription brands.

BioChain to acquire exclusive development and commercial license for China.

The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures.

Seventeen abstracts to be presented, including new analyses from the Phase III ARISTOTLE and AMPLIFY clinical studies and from real-world databases.

Approximately 25% of its headquarter positions to be affected.

The comprehensive range of punches and dies on display will include I Holland’s recently developed, XDF (eXtended Dwell Flat) punches.

The facility will produce APIs for a range of Novo Nordisk's current and future GLP-1 and insulin products.

Lialda patent upheld and extends through 8 June 2020.

Jury’s verdict upholds patent protections that are essential to the development of new medical treatments.

Recognized for advancing clinical research in Asia, speeding development for customers.

Survey about product launch challenges finds instances of demand forecasts off by more than 50%, leading to sales losses and reputation damage.

Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA.

Increasing prevalence of osteoporosis and growing ageing population coupled with new product launches to drive US osteoporosis drugs market through 2021.

New ready-to-use assays enable quick and simple generation of precise biosimilar comparability data.

Placon, spun out from Blend Therapeutics, to pursue development of next generation cytotoxic oncology drugs.

Gains full-rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program.

The newly allowed Patent covers Akers Bio's proprietary protein preparation which serves as the antigen and biologically active component of the tests.

Thermo Scientific Sorvall BIOS 16 centrifuge designed to provide simplified, flexible bioprocessing.

Highest product protection and maximum flexibility.

In addition to the new products, samples from I Holland’s current range of multi-tips and PharmaCote treatments and coatings will be on display.

Upon completion, the seven story building will cover a total of 8,000 m2 and include in its core a cleanroom with supportive media systems.

Penntech is a global provider of complete vial handling solutions covering washing, sterilization, filling, stoppering, capping and both tray and freeze dryer loading/unloading equipment.

Genevac compares use of a rotary evaporator and the Genevac Rocket Synergy evaporator, for the batch concentration of 2 L of winterised cannabis extract in ethanol.

Company's chairman of the board says he is confident that the company will be able to rebuild its reputation and thrive under new leadership.

ModiQuest will screen their high class in-house phage display libraries, ModiPhage.

Collaboration includes discovery programme for CAR-T cell-based oncology therapies.

The company believes it is a "first applicant" to file an ANDA for the generic version of Abraxane.

Under the new structure, Apotex will now operate along three core Lines of Business: Global Generics, Specialty Pharma and Global APIs.

The Board will now conduct a formal search for a successor and will consider internal and external candidates for the role.

The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines.

Proceedings on damages and an injunction against Sanofi and Regeneron will follow.

Companies say they plan to appeal the judgement.

Merger creates fast growing, global provider of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and manufacturing.

Global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.

The Postnova AF2000 MultiFlow reported to offer more flexibility, better performance and more robust results than any system before.

Report assesses trends by chemistry type, application type, functionalities and regions to offer analytical insights about the potential demand emerging for particular pharmaceutical excipients in specific regions.

As part of the approval, Teva has agreed to the divestment of certain overlapping molecules in 24 European countries.

The company has officially opening its second office, which is dedicated to the support of the ongoing and future projects for business partners from the West Coast of US.

Collaboration will use Siteseeker — a new ‘phenotypic’ screening platform that exploits the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome — to find new therapeutic options.

FDA requested additional CMC information for the Multi-Dose Preservative-Free bottle.

Acquisition enhances Lupin’s scale in the US generic market and broadens Lupin’s pipeline in dermatology, controlled substance products and other high-value and niche generics.

Facility being operated by Avid Bioservices subsidiary with capacity to potentially generate additional $40 million in annual revenue.

Dr Anders Lonner has stepped down as a director due to other priorities and personal commitments.

Used to demonstrate the use of statistical methodologies of Principal Components Analysis and Design of Experiments.

Instrument of the Year for Thermo Scientific Dionex Ion Chromatography portfolio.

The investment will enable higher throughput of samples, and electronic data capture to ensure integrity of information in regulatory submission and acceptances.

The two companies will pursue their own distinct growth strategies.

This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more...

With these new investments, Grifols increases its production capacity to continue covering the expected growing demand in the plasma-derived products until 2028–2030.

GBI Research says the pipeline may significantly alter the clinical and commercial landscape of the disease market over the next decade.

Acquisition will strengthen McKesson's position in Canada's pharmaceutical supply chain.

The launch represents a a key milestone on the company's path to secure new product approvals from the FDA.

Certified quality of analytical services for developers of biologics and biosimilars .

Acticor Biotech is developing an antibody fragment (Fab) considered as a first-in-class anti-thrombotic agent without bleeding risk in the primary treatment of ischemic strokes.

Blueberry Therapeutics is set to create safe, effective “nanomedicines” to treat a number of unmet clinical needs.

The company plans to introduce the new brand to its 43,000 employees around the world prior to launching the brand externally.

Chem-space.com online searchable marketplace features over 15 million compounds.

Moventig is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).

J. Michael Pearson to return as CEO following illness, effective immediately.

GBI Research report says that despite steady market growth, various unmet needs remain and a cure is yet to be found.

Analysis, trends and opportunities report 2016–2020 — key vendors: General Electric, Pall Corporation, 3M.

Cobra and CPI will develop in depth scientific and technical understanding to allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors.

Acquired site manufactures enzyme-based fermentation products and intermediates for the pharma industry.

£22 million investment in Liverpool by global biopharma company.

SigNature DNA offers authenticity and traceability for pharmaceutical global supply chains.

Retrofit ensures long-term process reliability.

BalanCD CHO Feed 4 is a chemically-defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells.

Agreement will leverage both Bespak and Aesica capabilities.

Adds an important technology in the filling of injectable beta lactams with sales to the US and European markets.

Valid Insight’s launch aims to meet the market access challenges facing new medicines, helping life science research to translate into real-world benefits for patients and society.

The agreements with ViiV Healthcare do not impact BMS’s marketed HIV medicines, including Reyataz, Evotaz, Sustiva and Atripla.

FDA provides GDUFA goal date of 28 March 28 2017

Alliance to provide drug discovery customers access to industry leading ion channel and transporter technologies.

The first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management.

Dublin headquarters central to European and global growth strategy.

Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma.

Expansion reflects critical role of MSD’s Irish sites in wider global network.

The acquisition of InvaGen Pharmaceuticals provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved during the next 4 years.

Athenex to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo during the next 10 years.

Patent protects the composition of Rizaport and will be listed in the Orange Book upon approval of the product by FDA.

Designed for use in biotechnological applications, especially for membrane screening and small-volume process development.

Lilly plans to seek permission to appeal the ruling.

Leading CDMO is granted both the WorldStar Award for Vetter-Ject and a 2016 CMO Leadership Award.

Symbiosis Pharmaceutical Services has picked-up several new clients in North America, which has primarily been driven by companies looking for small-scale aseptic manufacturing capabilities to support clinical trials.

Compatibility and testing of nested container and closure systems to help pharmaceutical companies manufacture parenteral medicines.

Combining ThioLogics' site-specific conjugation chemistry with Albumedix's drug delivery platform enables the creation of next-generation albumin drug conjugates.

Responding to the needs of users in the laboratories, Sartorius presents a new range of mechanical pipettes with a perfectly balanced design offering reliability, accuracy and comfortable use.